芳基乙酸类衍生物的设计、合成与抗过敏活性研究
Design, Synthesis and Anti-Allergic Activity Evaluation of Aryl-Acetic Acid Derivatives
DOI: 10.12677/HJMCe.2014.23006, PDF,   
作者: 周海平, 董广平, 徐云根：中国药科大学药物设计与优化江苏省重点实验室，南京；金雨婷, 朱启华：中国药科大学药物化学教研室，南京；卞学国：南京医工医药有限公司，南京
关键词: 芳基乙酸；合成；抗过敏；生物活性；Arylacetic Acids； Synthesis； Anti-allergic； Biological Activity
摘要: 目的：为了获得活性好、副作用小的DP受体拮抗剂，设计和合成芳基乙酸类衍生物。方法：以取代的苯酚、1,2-二溴乙烷以及香豆酸为原料，通过醚化、水解、酰胺化、水解等反应合成目标化合物，并研究其对烟酸诱导血管扩张效应的抑制活性。结果：合成了5个目标化合物，活性筛选结果表明，化合物I-4和I-5的活性优于阳性药(拉罗匹仑)。结论：化合物I-4和I-5对烟酸引起的血管扩张具有抑制作用，值得进一步研究。
Abstract: Objective: To discover novel DP receptor antagonists with higher potency and less side-effect, several arylacetic acid derivatives were designed and synthesized. Method: A series of title com-pounds were synthesized by etherification, hydrolysis, amidation and hydrolysis on the basis of substitutional phenol, 1,2-dibromoethane and coumarate. All the target compounds were evaluated by the model of niacin-induced vasodilation. Results: 5 title compounds were synthesized. The results of biological evaluation showed that the compounds I-4 and I-5 exhibited more potency than positive drug (Laropiprant). Conclusion: The compounds I-4 and I-5 showed potent inhibitory effect on niacin-induced vasodilation and would be valuable for further investigation.
文章引用：周海平, 金雨婷, 卞学国, 朱启华, 董广平, 徐云根. 芳基乙酸类衍生物的设计、合成与抗过敏活性研究[J]. 药物化学, 2014, 2(3): 38-45. https://dx.doi.org/10.12677/HJMCe.2014.23006

参考文献

[1] Lewis, R.A., Soter, N.A., Diamond, P.T., Austen, K.F., Oates, J.A., et al. (1982) Prostaglandin D2 generation after ac-tivation of rat and human mast cells with anti-IgE. Journal of Immunology, 129, 1627-1631.
[2] Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., et al. (2000) Prostaglandin D2 as a mediator of allergic asthma. Science, 287, 2013-2017.
[3] Kabashima, K. and Narumiya, S. (2003) The DP receptor, allergic inflammation and asthma. Prostaglandins, Leukotrienes and Essential Fatty Acids, 69, 187-194.
[4] Norel, X. (2007) Prostanoid receptors in the human vascular wall. The Scientific World Journal, 7, 1359-1374.
[5] Hammad, H., de Heer, H.J., Soullie, T., Hoogsteden, H.C., Trottein, F. and Lambrecht, B.N. (2003) Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. Journal of Immunology, 171, 3936-3940.
[6] Yasui, K., Asanuma, F., Hiranoa, Y., Shichijoa, M., Deguchia, M. and Arimurab, A. (2008) Contribution of prostaglandin D2 via prostanoid DP receptor to nasal hyperresponsiveness in guinea pigs repeatedly exposed to antigen. European Journal of Pharmacology, 578, 286-291.
[7] Torisu, K., Kobayashi, K., Iwahashi, M., Nakai, Y., et al. (2004) Development of prostaglandin D2 receptor antagonist: Discovery of highly potent antagonists. Bioorganic Medicinal Chemistry, 12, 4685-4700.
[8] Torisu, K., Kobayashi, K., Iwahashi, M., Nakai, Y., et al. (2004) Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists. Bioorganic Me-dicinal Chemistry, 12, 5361-5378.
[9] Torisu, K., Kobayashi, K., Iwahashi, M., Nakai, Y., et al. (2004) Discovery of orally active prostaglandin D2 receptor antagonists. Bioorganic Medicinal Chemistry Letters, 14, 4891-4895.
[10] Torisu, K., Kobayashi, K., Iwahashi, M., Egashira, H., et al. (2005) Development of a prostaglandin D2 receptor antagonist: Discovery of a new chemical lead. European Journal of Medicinal Chemistry, 40, 505-519.
[11] 董颖 (2006) 白花蛇舌草的化学成分及其质量研究. 硕士论文, 首都师范大学, 北京.
[12] 胡铮瑢, 刘玉环, 阮榕生, 彭红, 张锦胜, 刘成梅 (2009) 阿魏酸、对香豆酸碱法制备及应用研究进展. 食品科学, 21, 438-442.
[13] Lai, E. and Tobert, J.A. (2006) Method of treating pathological blushing. Patent No. WO 2006052798 A2.
[14] Sturino, C.F., O’Neill, G., Lachance, N., Boyd, M., et al. (2007) Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]- aceticacid (MK-0524). Journal of Medicinal Chemistry, 50, 794-806.
[15] K•程, M•G•沃特斯, K•M•梅特斯, G•奥内尔 (2006) 治疗动脉粥样硬化、血脂异常及相关病症的方法和药物组合物. 中国专利: 1787819.